Buscar resultados de ensayos clínicos
Coxsackievirus Infections - 25 Studies Found
Estado | Estudiar |
Completed |
Nombre del estudio: A Safety Study of Two Intratumoural Doses of Coxsackievirus Type A21 in Melanoma Patients Condición: Stage IV Melanoma Fecha: 2007-02-19 Intervenciones: Drug: Coxsackievirus A21 Two doses of drug, separated by 48 hours |
Recruiting |
Nombre del estudio: Study of Intratumoral CAVATAK™ (Coxsackievirus A21) and Ipilimumab in Patients With Advanced Melanoma Condición: Melanoma Fecha: 2014-11-26 Intervenciones:
|
Completed |
Nombre del estudio: Intratumoural Administration of Coxsackievirus A21 for the Control of Malignant Melanoma Condición: Malignant Melanoma Fecha: 2005-10-07 Intervenciones: Drug: Coxsackievirus A21 |
Completed |
Nombre del estudio: Coxsackie Virus A21 Administered Intravenously (IV) for Solid Tumour Cancers Condición:
Fecha: 2008-03-07 Intervenciones: Drug: CVA21 IV infusion, dose escalation of one or two infusions of escalating strength |
Terminated |
Nombre del estudio: A Study of the Intratumoural Administration of CAVATAK to Head and Neck Cancer Patients Condición: Head and Neck Cancer Fecha: 2009-01-29 Intervenciones: Biological: Coxsackievirus A21 1, 3 or 6 doses of CAVATAK (10^9 TCID50) at 48 hour intervals. |
Recruiting |
Nombre del estudio: Phase I Study of Intratumoral CAVATAK™ and Pembrolizumab in Subjects With Advanced Melanoma Condición: Melanoma Fecha: 2015-09-30 Intervenciones:
|
Completed |
Nombre del estudio: A Study of Intratumoral CAVATAK™ in Patients With Stage IIIc and Stage IV Malignant Melanoma Condición: Malignant Melanoma Fecha: 2010-10-20 Intervenciones: Biological: Coxsackievirus A21 (CVA21) CVA21 is a live oncolytic virus preparation derived from the non- |
Completed |
Nombre del estudio: Efficacy and Safety of Intratumoral CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks Condición: Melanoma Fecha: 2012-07-05 Intervenciones: Biological: Coxsackievirus A21 |
Completed |
Nombre del estudio: Safety and Clinical Activity of CAVATAK™ Alone or With Low Dose Mitomycin C in Non-muscle Invasive Bladder Cancer Condición: Non-muscle Invasive Bladder Cancer Fecha: 2014-12-07 Intervenciones:
|
Recruiting |
Nombre del estudio: Systemic Treatment Of Resistant Metastatic Disease Employing CVA21 and Pembrolizumab in Non-small Cell Lung Cancer and Bladder Cancer (STORM/ KEYNOTE-200) Condición:
Fecha: 2014-01-19 Intervenciones: Biological: CVA21 |